# ClinicalTrials.gov record NCT00774930

> PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide.

- Evidence object: `story:clinicaltrials-gov-nct00774930-lanreotide:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-10-14
- Source checked: 2026-07-30
- Published by PeptideScanner: 2026-08-14
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct00774930-lanreotide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00774930-lanreotide-v1.json
- Content SHA-256: `9b9ec001c1d6f207d3b626ca143c9b559707a62b49e7f38f8b2a8875b3e1be62`

## Claims and source pins

### Headline

ClinicalTrials.gov record NCT00774930 ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

### Summary

PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT00774930 at 2026-07-30T19:34:18.792Z. Its registry update date was 2022-10-14, and PeptideScanner's reviewed identity mapping was lanreotide. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct00774930-2022-10-14-2552601a3948`](#source-ctg-observation-nct00774930-2022-10-14-2552601a3948))

## Sources

<a id="source-ctg-observation-nct00774930-2022-10-14-2552601a3948"></a>
- **ClinicalTrials.gov record NCT00774930 · retained source version 2022-10-14:2552601a394812b0cf57f21a1e1ce77b6c64078dcac3c0d1afa181d9232d57ac** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT00774930) (`ctg-observation-nct00774930-2022-10-14-2552601a3948`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT00774930." Version 1, published 2026-08-14. https://peptidescanner.com/evidence/v1/objects/clinicaltrials-gov-nct00774930-lanreotide-v1.json SHA-256: 9b9ec001c1d6f207d3b626ca143c9b559707a62b49e7f38f8b2a8875b3e1be62.